Dr. Catherine C. McCuaig becomes New President of Canadian Dermatology Association
OTTAWA, June 29, 2021 (GLOBE NEWSWIRE) -- Canadian Dermatology Association (CDA) is pleased to announce the appointment of Dr. Catherine C. McCuaig to the position of CDA President, effective June 28, 2021.
Dr. McCuaig brings to the Association her impressive leadership experience as seen in the Society for Dermatology of Montreal as president for nine years, chair of the Atlantic Dermatology meeting 2014, co-chair of the Canadian Lymphedema Framework, and fellowship director Sainte Justine UHC since 2013. In addition, Dr. McCuaig has spearheaded two multidisciplinary clinics in epidermolysis bullosa and lymphedema for children in Montreal. Dr. McCuaig has also authored over one hundred peer reviewed articles as well as 10 dermatology textbook chapters.
Dr. McCuaig earned her medical doctorate at Queens University, Kingston. She completed her residency training at University of Toronto, dermatology at McGill University, with a pediatric fellowship in dermatology and laser under Dr. James Rasmussen at the University of Michigan. Dr. McCuaig is currently a pediatric dermatologist at Sainte-Justine University Hospital Center, and a clinical professor at the University of Montreal.
As President, Dr. McCuaig plans to focus on enhancing the life long dermatology medical specialty training in Canada. “I will work to ensure that education for residents and practicing dermatologists remains at the forefront of our Association.”
“Through the pandemic, we have learned how privileged we are to live in Canada, thanks to its public health care system, and governments that aid those in need…Evermore, we have learned how important it is to support each other, and grow through the exchange of ideas, practical tips, and knowledge in dermatology,” said Dr. McCuaig. “In addition, I will work hard to help the CDA be more active on social media platforms, as well as help to promote our specialty to our colleagues, media, and Canadian public.”
Dr. McCuaig begins as President, Canadian Dermatology Association for a one-year term, effective June 28, 2021.
ABOUT THE CDA
The Canadian Dermatology Association, founded in 1925, represents Canadian certified dermatologists. The association provides easy access to a reliable source of medical knowledge on dermatology. CDA exists to advance the science and art of medicine and surgery related to the care of the skin, hair and nails; provide continuing professional development for its members; support and advance patient care; provide public education on sun protection and other aspects of skin health; and promote a lifetime of healthier skin, hair and nails. By doing so, CDA informs and empowers both medical professionals and the Canadian public. To learn more about what the work CDA does visit dermatology.ca and join the conversation on twitter.com/CdnDermatology, facebook.com/CdnDermatology, or instagram.com/canadiandermatologyassociation/.
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-621 in Combination With Doxorubicin in Leiomyosarcoma
CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first patient with TTI-621 (SIRPα-IgG1 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with doxorubicin in a Phase 1b/2 study in leiomyosarcoma (LMS).
TTI-621 binds CD47, an innate immune checkpoint that binds SIRPα and delivers a "don’t eat me" signal to suppress macrophage phagocytosis. Overexpression of CD47 can allow tumor cells to escape immune surveillance. TTI-621 is a fusion protein consisting of the CD47 binding domain of SIRPα linked to the Fc region of human IgG1. It is designed to enhance phagocytosis and tumor cell destruction by blocking the CD47-SIRPα interaction and delivering an activating (“eat me”) signal to macrophages. The IgG1 backbone can also activate NK cell-mediated anti-tumor activity. Published preclinical studies suggest that anti-CD47 agents may exhibit anti-tumor activity against LMS cells.
“The dosing of this patient marks the beginning of the first Phase 1b/2 solid tumor clinical trial for Trillium,” commented Dr. Ingmar Bruns, Trillium’s Chief Medical Officer. “We’re committed to exploring solid tumors and build upon our potentially best-in-class initial hematologic malignancy datasets.”
For newly diagnosed LMS patients, doxorubicin is considered part of standard of care. In this open-label Phase 1b/2 study, Trillium is adding TTI-621 to frontline doxorubicin and enrolling approximately 60 newly diagnosed LMS patients. The primary endpoints are safety and overall response rate.
“Metastisized LMS, the most common form of soft tissue sarcoma, is a serious disease with significant unmet need. We believe that the combination of TTI-621 and doxorubicin has the potential to provide benefit for these patients where few therapeutic options exist,” added Dr. Bruns.
About Trillium Therapeutics
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-622 and TTI-621, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable United States federal securities laws and forward-looking information within the meaning of Canadian securities laws (collectively, "forward-looking statements"). The use of words such as "may," "will, "could", "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "seeks," "endeavor," "potential," "continue" or the negative of such words or other similar expressions can be used to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, express or implied statements regarding the therapeutic potential of our programs, our clinical development plans and our expectations with respect to the timing of clinical development milestones, including with respect to enrolling patients in Phase 1b/2 studies in hematological and solid tumor malignancies. With respect to the forward-looking statements contained in this press release, Trillium has made numerous assumptions regarding, among other things: the impact of the COVID-19 pandemic on its operations, the effectiveness and timeliness of preclinical and clinical trials; and the completeness, accuracy and usefulness of the data. While Trillium considers these assumptions to be reasonable, these assumptions are inherently subject to significant scientific, business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors that could cause Trillium's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained in this press release. A discussion of risks and uncertainties facing Trillium appears in Trillium's Annual Report on Form 10-K for the year ended December 31, 2020, with the U.S. Securities Exchange Commission, each as updated by Trillium's continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Trillium disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes
All three doses of tirzepatide achieved superior A1C and weight reductions compared to semaglutide in data simultaneously presented at the American Diabetes Association's® 81st Scientific Sessions®
TORONTO, June 29, 2021 /CNW/ - Tirzepatide led to superior A1C and body weight reductions from baseline compared to injectable semaglutide 1 mg in 40-week results from Eli Lilly and Company's (NYSE: LLY) SURPASS-2 clinical trial, which were simultaneously published on June 25 in The New England Journal of Medicine (NEJM)1 and presented in a late breaking poster presentation during the American Diabetes Association's® (ADA) 81st Scientific Sessions®.2 These results, which will also be featured during an ADA-sponsored symposium on Tuesday, June 29, showed that all three tirzepatide doses achieved greater A1C and weight reductions compared to semaglutide.
Additionally, a prespecified exploratory composite endpoint was evaluated, which comprised of participants who achieved an A1C level less than or equal to 6.5 per cent and weight loss of 10 per cent or greater, while not experiencing hypoglycemia less than 3 mmol/L or severe hypoglycemia. Across the three doses of tirzepatide, 32 per cent (5 mg), 51 per cent (10 mg) and 60 per cent (15 mg) of participants achieved this composite endpoint compared to 22 per cent of participants taking semaglutide 1 mg.1,2
The overall safety profile of tirzepatide was similar to the well-established glucagon-like peptide-1 (GLP-1) receptor agonist class. Across all treatment arms, the most commonly reported adverse events were gastrointestinal.
"Tirzepatide delivered superior A1C and weight reductions compared to semaglutide. The 15 mg dose of tirzepatide achieved less than or equal to 6.5 per cent combined with a weight loss of 10 per cent or greater, in 60 per cent of patients, without clinically significant hypoglycemia. The ability to achieve these challenging treatment goals is highly meaningful to clinicians and people living with type 2 diabetes," said Dr. Alice Cheng, MD, FRCPC, Endocrinologist, Trillium Health Partners & Unity Health Toronto, Associate Professor, University of Toronto. "These are impressive findings, and if approved, tirzepatide will be an exciting and promising new treatment option for Canadians with type 2 diabetes."
Tirzepatide is a novel investigational once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that integrates the actions of both incretins into a single molecule, representing a new class of medicines being studied for the treatment of type 2 diabetes. Semaglutide is a GLP-1 receptor agonist, and 1 mg is the highest dose of semaglutide that is approved by Health Canada for the treatment of type 2 diabetes.
SURPASS-2 was a 40-week, randomized, open-label trial comparing the efficacy and safety of tirzepatide to semaglutide as an add-on to metformin in adults with type 2 diabetes. The study randomized 1,879 participants, who had a mean duration of diabetes of 8.6 years, a baseline A1C of 8.28 per cent and a baseline weight of 93.7 kg.
For both estimands,i all three doses of tirzepatide demonstrated superior A1C and body weight reductions compared to semaglutide 1 mg. Specifically, results in the efficacy estimandii showed:
Percentage of participants achieving A1C <5.7%: 29% (5 mg, not controlled for type 1 error), 45% (10 mg), 51% (15 mg), 20% (semaglutide)
The treatment-regimen estimandiii results were consistent with topline results and showed that tirzepatide led to A1C reductions of -2.01% (5 mg, p=0.018), -2.24% (10 mg, p<0.001) and -2.30% (15 mg, p<0.001) compared to semaglutide at -1.86%, and weight reductions of -7.6 kg (5 mg), -9.3 kg (10 mg) and -11.2 kg (15mg) compared to semaglutide at -5.7 kg, all p<0.001.
For the treatment-regimen estimand,iii all three doses of tirzepatide delivered superior A1C and body weight reductions compared to semaglutide. Greater percentages of participants achieved an A1C of less than 7 per cent across all three doses compared to semaglutide, with statistical significance met for 10 mg and 15 mg, but not for 5 mg. Specifically:
Hypoglycemia less than 3 mmol/L was reported in 0.6 per cent (5 mg), 0.2 per cent (10 mg) and 1.7 per cent (15 mg) of participants in the tirzepatide arms and in 0.4 per cent of participants in the semaglutide arm.
In an additional exploratory endpoint, all three doses of tirzepatide led to favorable changes from baseline in fasting lipids. Specifically, at the highest dose of tirzepatide (15 mg): triglycerides were reduced by 24.8 per cent, very low-density lipoprotein (VLDL) cholesterol was reduced by 23.7 per cent, and high-density lipoprotein (HDL) cholesterol was increased by 7.1 per cent.2
The most commonly reported adverse events across all treatment arms were gastrointestinal and mostly mild- to moderate, including nausea (17.4 per cent [5 mg], 19.2 per cent [10 mg], 22.1 per cent [15 mg], 17.9 per cent [semaglutide]), diarrhea (13.2 per cent [5 mg], 16.4 per cent [10 mg], 13.8 per cent [15 mg], 11.5 per cent [semaglutide]) and vomiting (5.7 per cent [5 mg], 8.5 per cent [10 mg], 9.8 per cent [15 mg], 8.3 per cent [semaglutide]). Treatment discontinuation rates due to adverse events were 6.0 per cent (5 mg), 8.5 per cent (10 mg), 8.5 per cent (15 mg) and 4.1 per cent (semaglutide).
"These data position tirzepatide as an innovative, new treatment option that could change the treatment landscape for type 2 diabetes," said Dr. Doron Sagman, vice president, R&D and Medical Affairs, Eli Lilly Canada. "The exceptional results from this study suggest that tirzepatide could help people with type 2 diabetes and their healthcare providers achieve their A1C and weight treatment goals."
SURPASS-2 is the second of five global registration studies for tirzepatide in type 2 diabetes, all of which have been completed. Lilly intends to submit the full registration package to regulatory authorities by the end of 2021.
About tirzepatide Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with a GLP-1 receptor agonist, may result in greater effects on glucose and body weight. Tirzepatide is in phase 3 development for blood glucose management in adults with type 2 diabetes and for chronic weight management. It is also being studied as a potential treatment for non-alcoholic steatohepatitis (NASH).
About SURPASS-2 and the SURPASS clinical trial program SURPASS-2 (NCT03987919) is a 40-week, multi-center, randomized, parallel, open-label trial comparing the efficacy and safety of tirzepatide 5 mg, 10 mg and 15 mg to semaglutide in adults with type 2 diabetes inadequately controlled with ≥1500 mg/day metformin alone. The trial randomized 1,879 study participants across Canada, the U.S., Argentina, Australia, Brazil, Israel, Mexico and the UK in a 1:1:1:1 ratio to receive either tirzepatide 5 mg, 10 mg or 15 mg or semaglutide 1 mg. The primary objective of SURPASS-2 was to demonstrate that the two higher doses of tirzepatide (10 mg and/or 15 mg) led to non-inferior A1C reductions from baseline compared to semaglutide after 40 weeks in people with type 2 diabetes. Key secondary objectives included non-inferior A1C reductions from baseline for tirzepatide 5 mg; superior A1C and body weight reductions from baseline and greater percentages of participants achieving an A1C less than 7 per cent across all three tirzepatide doses; and greater percentages of participants achieving an A1C less than 5.7 per cent for tirzepatide 10 mg and 15 mg compared to semaglutide. Additional secondary endpoints not controlled for type 1 error included percentage of participants achieving an A1C less than 5.7 per cent for tirzepatide 5 mg compared to semaglutide. Study participants had a mean A1C between 7 per cent and 10.5 per cent and a BMI greater than or equal to 25 kg/m2. All participants in the tirzepatide treatment arms started the study at a dose of tirzepatide 2.5 mg once weekly and then increased the dose in a step-wise approach at four-week intervals to their final randomized maintenance dose of 5 mg (via a 2.5 mg step), 10 mg (via steps at 2.5 mg, 5 mg and 7.5 mg) or 15 mg (via steps at 2.5 mg, 5 mg, 7.5 mg, 10 mg and 12.5 mg). Participants in the semaglutide treatment arm started the study at a dose of semaglutide 0.25 mg once weekly for four weeks, then increased the dose to 0.5 mg for four weeks and then reached the final dose of 1 mg.
The SURPASS phase 3 global clinical development program for tirzepatide has enrolled more than 19,000 people with type 2 diabetes across 10 clinical trials, five of which are global registration studies.
About Diabetes Approximately 11 million Canadians are living with diabetes or prediabetes. Roughly 90 per cent of people living with diabetes have type 2 diabetes.3
About Lilly Diabetes Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research, collaboration and quality manufacturing we strive to make life better for people affected by diabetes and related conditions. We work to deliver breakthrough outcomes through innovative solutions—from medicines and technologies to support programs and more.
About Eli Lilly Canada Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by Colonel Eli Lilly, who was committed to creating high quality medicines that meet people's needs, and today we remain true to that mission in all our work. Lilly employees work to discover and bring life-changing medicines to people who need them, improve the understanding and management of disease, and contribute to our communities through philanthropy and volunteerism.
Eli Lilly Canada was established in 1938, the result of a research collaboration with scientists at the University of Toronto, which eventually produced the world's first commercially available insulin. Our work focuses on oncology, diabetes, autoimmunity, neurodegeneration, and pain. To learn more about Lilly Canada, please visit us at www.lilly.ca.
For our perspective on issues in healthcare and innovation, follow us on twitter @LillyPadCA and @LillyMedicalCA.
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about tirzepatide as a potential treatment for patients with diabetes and reflects Lilly's current beliefs. However, as with any such undertakings, there are substantial risks and uncertainties in the process of drug development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date, that tirzepatide will prove to be a safe and effective treatment for diabetes, that tirzepatide will receive regulatory approvals or authorizations, or be commercially successful. For a further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, please see Lilly's most recent Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
REFERENCES
1. Frias, J.P, et. al. (2021). Tirzepatide vs. Semaglutide Once Weekly for Patients with Type 2 Diabetes. The New England Journal of Medicine, www.nejm.org/doi/full/10.1056/NEJMoa2107519.
2 Frias, J.P. Efficacy and Safety of Tirzepatide vs. Semaglutide Once Weekly as Add-On Therapy to Metformin in Patients with Type 2 Diabetes. Abstract 84-LB. Presented virtually at the American Diabetes Association's 81st Scientific Sessions; June 25-29.
i Treatment differences for two estimands – efficacy and treatment-regimen – were evaluated for three tirzepatide doses (5 mg, 10 mg and 15 mg) compared to semaglutide 1 mg.
ii Efficacy estimand represents efficacy prior to discontinuation of study drug or initiating rescue therapy for persistent severe hyperglycemia.
iii Treatment-regimen estimand represents the efficacy irrespective of adherence to the investigational medicine or introduction of rescue therapy for persistent severe hyperglycemia.
SOURCE Eli Lilly Canada Inc.
What Are Signs Of Insulin Resistance And How Can You Reverse It?
Three-Time Champion Fitness Competitor Available For InterviewsChristine Hronec, an award-winning chemist and three-time champion fitness competitor, nutrition, and exercise expert is available for interviews.
1. Hemoglobin A1c test
The best way to determine whether or not someone has insulin resistance conclusively is to get your hemoglobin A1c tested. Just keep in mind, that when you get your A1c levels tested, it's an average of what's going on in your blood in the last thirty days. If your A1c levels are under 5.7, you are fine. Between 5.7 and I'd say about 6.4 is pre-diabetic. I'd say over 6.4 is diabetic.
2. Your fasting blood glucose
If your fasting blood glucose is over 100, that's also an indicator. But outside of the actual numbers, if you eat carbohydrates, and when you eat carbohydrates, you still feel hungry afterwards, and you feel like once the hunger switch is turned on, it does not go off, this is a very good sign that you have insulin resistance. And the reason why is because when you consume carbohydrates, it causes your blood sugar to go up. When your blood sugar goes up, what needs to happen is insulin is a messenger hormone, which is required to shuttle the glucose out of the blood and into the cells. However, some individuals do not have... that process doesn't go smooth for them. So, what that means is insulin is grabbing onto the glucose molecule, knocking on the door of yourself and trying to escort it inside. And what ends up happening is the cells are non-responsive. They're not answering the door. It's like they don't have a secret knock. And when that happens, the pancreas creates more insulin and more insulin and more insulin. We're trying to barge down the doors of these cells to get the glucose out of the bugs. It's a toxic system, a toxic state to have high blood sugar. So, when all of that occurs, you're starving on the cellular level, because we think of the food we consume, we think the end user of food is what? The stomach. No, the end user of that food is your cells. So, your cells still have not received energy, even though you are eating. So, if the cells are not receiving energy, they can't send the signal to the brain to tell you that you're full. So, you're going to keep eating and eating and eating, and it's just a recipe for disaster. Brain fog, just tired, hungry all the time - just crazy cravings.
How to reverse insulin resistance The only way to really get in front of it and intercede it is to break that cycle. And it's going to be hard at first, because a lot of people have to go through a sugar detox process, or they really need to start fueling their body off of healthy fats for fuel instead of carbs. But it can be treated with proper nutrition. I see people reverse out of the diabetic and pre-diabetic state using nutrition alone.
About Christine HronecChristine Hronec (https://gaugelife.com) is an award-winning chemist and three-time champion fitness competitor, nutrition, and exercise expert. Since founding her company Gauge Life in 2013, Christine has helped approximately 40,000 women transform their bodies and switch to a body-positive self-image. Her YouTube channel has over 25 million views. Christine has received awards from the American Chemical Society and was published in the American Institute of Chemical Engineers. Christine was part of the team that created Time magazine’s “Invention of the Year” for her work in the biotech field.
The Chopped Leaf invites you to savour summer
With fresh dishes perfect for the season
Oakville, ON, June 29, 2021 (GLOBE NEWSWIRE) -- The weather is heating up and The Chopped Leaf is ready to cool you down. Today, the brand announced the addition of two new limited-time salads and wraps to their menu. Focusing on fresh, quality ingredients that are paired perfectly with their exclusive signature dressings, these new chef-designed creations invite you to soak up and savour summer.
With record setting temperatures and a new season upon us, customers are looking for new, light and refreshing options they can enjoy in the sunshine. Hot temperatures and warm climates are known to suppress the appetite as a way to regulate the body temperature. People also naturally start to increase their water intake in order to stay hydrated. Drawing from this knowledge, bringing two fresh salads and wraps to their menu is a seamless fit for the season. Each of these dishes incorporates ingredients that their customers know and love, while introducing combinations the brand has never done before.
Chef Derek Easton, The Chopped Leaf’s Product and Development Manager, explains “the inspiration behind these dishes is simple: they are a combination of fan favourites and global trends. Utilizing fresh fruits and vinaigrettes in a salad as the months heat up, as well as incorporating plant-based protein are the two essential parts of each dish. These new menu items have been designed to help people feel fueled yet refreshed during the months when people tend to opt for lighter options.”
The Chopped Leaf launched their Summer Salad Naming Contest last month and gave customers the opportunity to submit their own creative entries for the chance to win a prize. This strategic move not only expanded the awareness of these new limited-time items coming to their menu, but engaged their audience and made them feel empowered.
Introducing The Chopped Leaf’s newest menu additions:
Meet Sun Goddess:
A fresh blend of chopped mix, tomatoes, crunchy cucumbers, carrots, green onions, crushed falafel, mozzarella and pita chips tossed in their savoury signature goddess dressing. It’s the fattoush salad, chop-style.
Meet Berry Breeze:
A sweet blend of spinach, cranberries, blueberries, pecans, red onions, feta, apples and pita chips, tossed in their fruit vinaigrette dressing.
For more information on this and other delicious, fresh menu offerings, visit the menu.
Pomerleau and the MUHC Foundation work toward revolutionizing cancer care across Canada
MONTREAL, June 28, 2021 (GLOBE NEWSWIRE) -- Pomerleau, one of Canada’s leading construction companies, is joining forces with the McGill University Health Centre (MUHC) Foundation to support a groundbreaking cancer project. With a $250,000 donation over five years, Pomerleau is supporting research led by Dr. Peter Metrakos, Cancer Research Program Lead at the Research Institute of the McGill University Health Centre (RI-MUHC). Using local engineering expertise in artificial intelligence, Metrakos’ work will significantly improve survival rates of patients diagnosed with stage IV colorectal cancer.
Colorectal cancer is the second leading cause of cancer death in Canadians and is responsible for more deaths than breast cancer or prostate cancer. Stage IV colorectal cancer is incredibly deadly, with a five-year survival rate of only 12 per cent.
“Pomerleau has had a long-standing collaboration with the MUHC that began with building the MUHC Research Institute and then evolved into a philanthropic affiliation. Like the MUHC, we value innovation, transformation and excellence and aspire to have a positive impact on the lives of the people we serve. We are proud to continue our partnership and support the kind of life-changing research that will save and improve countless lives.”
Pierre Pomerleau, President & CEO, Pomerleau
Using liquid biopsy techniques, Drs. Metrakos and Lazaris, with their team will help separate DNA, RNA, proteins and other constituent parts of the blood, to identify the ones associated with a patient’s cancer. Artificial intelligence (AI) will be used to identify patterns and insights into the data gathered from each patient’s blood sample. These patterns will then be used to create a test that will predict outcomes, providing a critical key to personalized treatment and improved survival.
“Our goal is to understand each individual’s cancer so we can provide precise and personalized treatment. Having support from Quebec industry means we can make these treatments a reality.”
Dr. Peter Metrakos, Cancer Research Program Lead, RI-MUHC
Quebec continues to be a leader in the field of artificial intelligence applied in health care and Dr. Metrakos’ work will drive innovation for years to come. With over 26,000 Canadians diagnosed with colorectal cancers each year, this project has the potential to affect millions of lives, from the patients going through cancer treatment to their families, friends, and colleagues.
“Pomerleau’s donation enables research done here in Quebec to impact patients and their families right across the country. We are grateful to be collaborating with a respected, forward-thinking company and for their confidence in medical innovations like this one.”
Julie Quenneville, President & CEO, MUHC Foundation
MEDTEQ+, funded by the Ministère de l’Économie et de l’Innovation, is providing matching funds for industry investment and donations. This process enables donor funds to leverage their philanthropic support and impact.
About the McGill University Health Centre Foundation The McGill University Health Centre (MUHC) Foundation raises funds to support excellence in patient care, research and teaching at the McGill University Health Centre, one of the top university hospitals in Canada. Our Dream Big Campaign to change the course of lives and medicine is raising millions of dollars to solve humanity’s deadliest puzzles: infectious diseases; end cancer as a life-threatening illness; fix broken hearts through innovative cardiac care; detect the silent killers—ovarian and endometrial cancers—early; create the best skilled health care teams in Canada; and much more. We are rallying our entire community to solve the world’s most complex health care challenges. www.muhcfoundation.com
About Pomerleau Pomerleau is one of Canada’s leading construction companies and a pioneer in sustainable buildings. It specializes in the building, infrastructure, civil engineering, and renewable energy sectors. The company also excels in virtual design and construction (VDC). Founded close to 60 years ago, the company employs up to 4,000 people at its nine regional offices and more than 150 worksites across the country. In 2020, Pomerleau was named one of Canada's Top 100 Employers. For more details about Pomerleau, visit www.pomerleau.ca.
Meningitis Canada Calls on Governments to Fund Meningitis B Vaccine
WATERLOO, Ontario, June 28, 2021 (GLOBE NEWSWIRE) -- In the wake of the tragic death of 19-year-old Kai Matthews of Halifax, Nova Scotia, Meningitis Foundation Canada (MFC) calls on all Canadian provinces and territories to include meningitis B on their routine immunization schedules.
“It is unconscionable and unacceptable that a vaccine to prevent the most common and deadly form of meningitis is not fully funded and included on all provincial and territorial routine immunization schedules. Kai Matthew’s heartbreaking death might have been prevented had he received either of the two available Health Canada-approved vaccines for the B strain that killed him,” said MFC spokesperson and Co-Chair Michael Redfearn.
Kai was a healthy, vibrant multi-sport athlete who had just finished his first year at Acadia University. Despite being approved, many young Canadians and their families are not aware of the meningitis B vaccines and therefore have not been immunized. If the COVID-19 pandemic has taught us anything, it has driven home the cold hard fact that vaccine prevention saves lives.
Students who are in close contact through living in college or university dorms or sharing beverages or utensils or through kissing and engaging in other behaviors are at greater risk of contracting meningitis. A blood infection with Neisseria meningitidis, the bacteria that causes meningococcemia and meningococcal meningitis, may not be recognized or diagnosed when an infected person starts to feel unwell. For this reason, vaccine prevention is the most important way to reduce serious illness.
Meningitis is a potentially deadly inflammation of the brain and spinal cord, which result from infection by bacteria, viruses, and fungi. Bacterial meningitis is the most severe type and is a medical emergency. It can strike quickly, be difficult to diagnose, and can lead to death in a matter of hours. There are effective vaccines now available to protect against many of the bacteria that cause meningitis and septicemia.
BforKai.com exists to help educate people about meningitis B and increase vaccination rates.
HealthPRO Announces Winner of #FacesofCanadianHealthcare Art Contest
Winner directs $25,000 donation to chosen Canadian healthcare facility
MISSISSAUGA, ON, June 28, 2021 /CNW/ - HealthPRO, Canada's group contracting provider for healthcare, is pleased to announce Maggie Coffin Prowse from Grand Bay-Westfield, New Brunswick as the winner of its #FacesofCanadianHealthcare national art contest.
Launched in March to pay tribute to the healthcare workers HealthPRO has been honoured to serve over the last 25 years, the contest received over 100 submissions from artists across nearly every Canadian province.
Earning the highest number of votes for her piece I See You, a reflection of nurses' comforting eyes, Ms. Coffin Prowse is taking home a $3,000 cash prize, and the opportunity to direct $25,000 to her chosen Canadian healthcare facility: Bobby's Hospice in Saint John, New Brunswick.
"This is a tremendous honour," said Maggie. "My aunt passed away from COVID and the last form of communication she received from a healthcare professional was through their eyes which is the focus of my piece. I'm very grateful for the opportunity to support Bobby's Hospice and my community with this incredible donation. Our healthcare system is driven by so many passionate and committed individuals whom I thank from the very bottom of my heart."
Brad Adams, Executive Director, Hospice Greater Saint John was thrilled to learn that they were selected as Maggie's charity of choice.
"Our ability to fundraise has been severely disrupted by COVID-19, so receiving this generous donation will have a massive impact on our organization! The staff, volunteers, patients and families of Bobby's Hospice congratulate Maggie for sharing her creativity to positively influence our community. We also extend our appreciation to HealthPRO for facilitating such an impactful contest and substantial donation during these trying times."
Renato Discenza, President and CEO at HealthPRO noted that this contest was a small way of showing tremendous appreciation for the healthcare professionals who make a difference in the lives of so many.
"As an organization that lives by Knowledge and Trust, I am incredibly grateful for the sacrifices of our healthcare professionals and that Canadians in need could trust in their knowledge, dedication and compassion throughout this pandemic and beyond."
Placing second and receiving a $2,000 cash prize for her submission The Price of Fortitude is Darlene Jordan Pfaff from London, Ontario and in third place, receiving a $1,000 cash prize, is Melissa Leah Bruglemans-LaBell from Airdrie, Alberta for her piece Coffee Break. To view all art pieces submitted, please visit www.facesofcanadianhealthcare.com.
About HealthPROHealthPRO is Canada's group contracting provider for healthcare. We put decades of knowledge and the purchasing volumes of more than 1,300-member healthcare facilities across Canada to work. Our members count on us to reduce the cost of products and services they use, improve patient safety, help maintain assurance of supply and pursue new ideas and innovations. The outcome is unprecedented buying power and market influence for Canadian healthcare facilities. For more information, please visit www.healthprocanada.com.
SOURCE HealthPRO Procurement Services Inc.
Canadian Dermatology Association Announces 2021 Award-Winning Dermatologists and the CDA Public Education Awards
OTTAWA, June 25, 2021 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association is proud to announce the recipients of the 2021 CDA Awards which recognizes certified dermatologists for their contributions to dermatology and the CDA Public Education Awards, which acknowledges excellence in furthering understanding of dermatologic issues and in encouraging healthy behaviour in the medical, surgical and cosmetic care of skin, hair and nails.
2021 CDA AWARDS Recognizing certified dermatologists for excellence in leadership, clinical care, education and research in the medical, surgical and cosmetic care of skin, hair and nails.
CDA Lifetime Achievement Award: Dr. Wayne Gulliver This award honours a CDA member, certified dermatologist who have made a significant and lasting impact in the field of dermatology, through their professional accomplishments as long-standing members of the Association, and who have earned the respect and admiration of their professional colleagues. Dr. Wayne Gulliver was honoured with the Lifetime Achievement award for his commitment to dermatology. More than 30 years ago, Dr. Gulliver was the first dermatologist to practice in Newfoundland and Labrador. He was a pioneer in his native province and a key player in transforming a non-existent dermatology service into a service today that is diverse and leading-edge. Dr. Gulliver’s continued advocacy to increase access to dermatology care in rural areas has enhanced the quality of healthcare for all people in the province. Dr. Gulliver’s contributions also extend into research and clinical expertise on a global scale. With more than 250 clinical trials and numerous publications, he was the first Canadian to receive the Albert Neisser Lecture Award for his ground-breaking research on hidradenitis suppurativa. He has also made novel contributions to areas that include melanoma, psoriasis epidemiology and therapeutics. Dr. Gulliver has also shown national leadership as CDA vice-president and as chair of the 1997 CDA Annual Conference in St. John’s.
CDA Award of Merit: Dr. Gordon Searles
This Award recognizes the excellence of leadership and outstanding contributions to the CDA and Canadian and international dermatology. CDA member and certified dermatologist, Dr. Gordon Searles received this Award for his substantial contributions to many areas of dermatology. He is recognized around the world for his experience in wound healing and complex dermatology conditions that overlap with internal medicine. Dr. Searles has been involved in dermatology education for more than 30 years at the University of Alberta and was one of the initiators of the Canadian Professors of Dermatology’s Residents Innovation and Vision in Education (DRIVE) program. His dedication to securing the future of dermatology has also been evident in his positions as President and Treasurer, serving on other influential CDA committees and with the Canadian Dermatology Foundation. Dr. Searles has also spent many hours advocating for equal access to medication and dermatology care for disadvantaged groups, and his involvement with Camp Liberté and the Canadian Skin Patient Alliance, demonstrate his deep humanity and commitment to patient care.
CDA Early Career Volunteer Award: Dr. Boluwaji Ogunyemi and Dr. Michele Ramien This Award recognizes residents, fellows, and new dermatologists who are committed to give back to society by contributing at a local, provincial, national or international level through volunteer activities that have a medical or dermatological aspect. This year, the Award recognized two outstanding CDA member recipients, Dr. Boluwaji Ogunyemi and Dr. Michele Ramien.
Dr. Boluwaji Ogunyemi received this Award for his leadership and health advocacy work. He was co-chair of the Residents and Fellows Society of the CDA during his residency at the University of British Columbia, representing the voice of residents to the CDA Board of Directors. He now gives a voice to marginalized groups, an effort that began early on when he chose to work with the most vulnerable populations in British Columbia, including in Vancouver’s Downtown East Side. Dr. Ogunyemi has continued in this spirit at Memorial University in Newfoundland, where he oversees Faculty of Medicine initiatives in health equality, Indigenous and global health, and community engagement. Clinically, he is advancing dermatological knowledge and care for people with skin of colour. Focusing on advocacy and leadership work on a national level, Dr. Ogunyemi is a member of the National Equality in Medicine Group, the Public Health Agency of Canada’s Ethics Consultative Group. He is also a physician advisor for Black Physicians of Canada and a board member with Canadian Doctors for Medicare.
Dr. Michele Ramien received this Award for her deep dedication to resident development, commitment to teaching and volunteering and patient advocacy. Upon starting her residency, Dr. Ramien became a leader and mentor, generously sharing her knowledge with residents and students, supporting them throughout their studies and early careers. Dr. Ramien was nominated by residents for teaching awards and has received the CDA Resident and Fellows Society Teaching Award and the Professional Association of Resident Physicians of Alberta Clinical Teaching Award. Dr. Ramien’s involvement with Camp Liberté began in her residency years reflecting her dedication to volunteer initiatives and giving back to her community. She ascended into leadership roles on the Camp’s Board of Directors, becoming Vice President in 2016. In Alberta, Dr. Ramien continued her passion for helping children as an on-site volunteer at the Brag Creek camp. Dr. Ramien’s impressive dedication of giving back to the community reflects her energy and commitment to dermatology volunteer initiatives and her volunteer work will continue as she steps into the Vice President position on the CDA Board of Directors.
CDA Research Award in Dermatology: Dr. Laurence Mainville This Award is presented for the best manuscript submitted for original work, not previously published and relevant to dermatology. The award recognizes excellent work intended to expand, direct, define or assist in the understanding and/or treatment of dermatologic disease. This year’s recipient is CDA Member, Dr. Laurence Mainville, PGY 3 resident at the Université Laval. Dr. Mainville is recognized for her outstanding work as lead author of the research article titled “Effect of Nicotinamide in Comparison with Placebo, Vehicle, Standard of Care, No Treatment or Other Treatment with Neutral or Weak Effect in Skin Cancers Chemoprophylaxis: As Systematic Review and Meta-Analysis.” Dr. Mainville’s important research contributes to advancing the field and striving toward optimal preventative treatment for patients with skin cancer.
CDA Resident’s Writing Award: Dr. Suzel Fournier This Award recognizes dermatology residents who contribute and share their expertise and experiences within the dermatology community. The Award is presented to a Resident Associate of the CDA who has contributed significant knowledge in the dermatology field through written material in CDA publications. This year’s recipient is CDA member Dr. Suzel Fournier, a fourth-year resident at the Université Laval for her article “Prospective Clinical Trial Comparing Curettage and Cryosurgery to Curettage and Electrodesiccation in the Management of Minimally Invasive Basal and Squamous Cell Carcinomas” which was published in the CDA Journal of Cutaneous Medicine and Surgery. The research of comparative treatments educates dermatologists on cure rates, to enhance how they assist patients with their treatment options for these types of skin cancers.
CDA-RFS Teaching Awards The CDA-RFS Teaching Awards recognize Canadian residents or fellows and teachers who have made an outstanding contribution to peer-resident and resident teaching. Congratulations to the following CDA member Award recipients:
Resident Teaching Award: Dr. Zeinah AlHalees, McGill University
Resident Teaching Award: Dr. Reetesh Bose, University of Ottawa
Clinical Teaching Award: Dr. Jérome Coulombe, CHU Ste-Justine
Clinical Teaching Award: Dr. Kucy Pon, Sunnybrooke Hospital
CDA-RFS Excellence in Leadership Award: Dr. Malika Ladha and Dr. Megan Lim This Award is a national award given annually up to two Canadian dermatology residents and fellows who have made outstanding contributions at local, provincial, national, or international level through leadership initiatives and contributions that have a medical or dermatologic aspect. Congratulations to the following recipients: Dr. Malika Ladha and Dr. Megan Lim
Impact Factor 100 Award: Dr. Julia Carroll This Award is a national award recognizing one member of the dermatology community who has made outstanding contributions to the goals, efforts, and mission of the CDA-RFS. Congratulations to CDA member, certified dermatologist, Dr. Julia Carroll.
JCMS Lecture Award: Dr. David Zloty
The JCMS Lecture is aimed at honouring a contributing author whose work has attracted much attention in the last year by inviting them to deliver a presentation within their area of expertise at the Canadian Dermatology Association’s (CDA) annual conference. Dr. Zloty received the JCMS Lecture award for his article Age, Psychology, and Practice Patterns.
2021 CDA PUBLIC EDUCATION AWARDS The CDA Public Education Awards recognize excellence in furthering the understanding of dermatologic issues and encouraging healthy behaviour in the medical, surgical, and cosmetic care of skin, hair, and nails. The competition was open to media, not-for-profit groups and industry for projects or activities completed between January 1, 2020 and December 31, 2020.
CDA PUBLIC EDUCATION AWARDS: NOT-FOR-PROFIT CATEGORY French version of an educational video on Mohs surgery for patients: CHU de Québec-Université Laval Dr. Marie-Michèle Blouin and Dr. Laurence Mainville, PGY3 resident, Université Laval Mohs surgery has always been verbally explained to French patients due to a lack of French educational support available. To provide an unmet need in patient education for this procedure, Dr. Laurence Mainville, a dermatology resident at the Université Laval, working under the supervision of Mohs surgeon, Dr. Marie-Michèle Blouin, produced a French version of an English-version video summarizing Mohs surgery. The video explains the surgery in simple and accessible language for French speaking patients. https://www.youtube.com/watch?v=XDLWUdK8v40&t=1s
CDA PUBLIC EDUCATION AWARDS: NOT-FOR-PROFIT CATEGORY Impact of COVID-19 on the Psoriasis and Psoriatic Arthritis Community in Canada Canadian Association of Psoriasis Patients, Canadian Psoriasis Network and Unmasking Psoriasis The Canadian Association of Psoriasis Patients, Canadian Psoriasis Network and Unmasking Psoriasis collaborated on a World Psoriasis Day 2020 initiative to raise awareness about psoriasis and psoriatic arthritis in Canada. A bilingual survey was conducted in the psoriasis community to understand the experiences of people living with these conditions during the pandemic. Results from the survey were used to raise awareness among federal government officials about the impacts for people living with these conditions before and during the pandemic and how access to care, treatment and services can be improved for psoriasis and psoriatic arthritis patients. Results were also sourced to inform a public awareness social media campaign and were developed into an infographic hosted on both the Canadian Psoriasis Network and Canadian Association Psoriasis Patient’s websites. canadianpsoriasis.ca/world-psoriasis-daywww.canadianpsoriasisnetwork.comunmaskingpsoriasis.org
CDA PUBLIC EDUCATION AWARDS: MEDIA - PRINT Dermatitis herpetiformis: Celiac disease of the skin | Priya Dhir The article takes readers on an insightful journey of learning about the skin condition dermatitis herpetiformis and its relation to Celiac Disease. DH affects approximately 25% of people with Celiac disease who typically have no gastrointestinal symptoms. Patients will see their family doctor or a dermatologist first before seeing a gastroenterologist. This raises the awareness on the collaborative approach required between general practitioners and specialists to assist patients with Dermatitis Herpetiformis and Celiac Disease. canadianskin.ca/images/magazine/Canadian_Skin_Spring2020_Eng.pdf
CDA PUBLIC EDUCATION AWARDS - INDUSTRY “The World’s Most Uncomfortable Bed – Québec Activation Campaign”| Sanofi-Genzyme Jean-Francois Boisvert The World’s Most Uncomfortable Bed campaign was first launched in 2019 to raise awareness of atopic dermatitis and its impact on quality of life, especially a restful night’s sleep. To experience what it is like to live with this condition, family members of a person with atopic dermatitis were invited to sleep for a night on a bed with a burlap pillow, lumpy mattress, and heating device. Following the successful and compelling campaign in 2019, the World’s Most Uncomfortable bed was introduced in Quebec in 2020. With pandemic restrictions an in-person experience was not possible, instead the campaign went virtual using Quebec celebrities, who experienced the uncomfortable bed and documented their experience on social media. One featured here: www.facebook.com/etienne.boulay.96/videos/405031500537996
ABOUT THE CDA
The Canadian Dermatology Association, founded in 1925, represents Canadian certified dermatologists. The association provides easy access to a reliable source of medical knowledge on dermatology. CDA exists to advance the science and art of medicine and surgery related to the care of the skin, hair and nails; provide continuing professional development for its members; support and advance patient care; provide public education on sun protection and other aspects of skin health; and promote a lifetime of healthier skin, hair and nails. By doing so, CDA informs and empowers both medical professionals and the Canadian public. To learn more about what the work CDA does visit dermatology.ca and join the conversation on twitter.com/CdnDermatologyfacebook.com/CdnDermatology or instagram.com/canadiandermatologyassociation/
Largest international review of serosurveys, done by Canadians, suggests that the global population remains vulnerable to COVID-19
MONTREAL, June 25, 2021 (GLOBE NEWSWIRE) -- SeroTracker, a Canadian research group, has published the largest study to date on the global spread of SARS-CoV-2 in the journal PLOS One. The study examined antibody survey data, which were published from January to December 2020, from 9.3 million people in 74 countries and found that the number of people who had a SARS-COV-2 infection, although widely variable globally, remained fairly low in the general population.
“Unfortunately, the results show that this global pandemic is not over,” says Dr. Niklas Bobrovitz, co-lead author and and Research Associate, Department of Critical Care Medicine, University of Calgary. “Despite the challenges in monitoring and limiting the spread of SARS-CoV-2 so far, many people are likely still susceptible to infection, which means that future spikes are possible. We need to continue adhering to public health measures, ensure equitable distribution of vaccines, and improve confidence in vaccination.”
“Last year, on average, studies around the world reported about 4.5% seroprevalence, meaning only 4.5% of people had antibodies to SARS-COV-2, suggesting a previous infection. Antibody tests can capture infections missed by diagnostic testing to give us a more accurate picture of the pandemic’s spread,” explains Rahul Arora, co-lead author and Adjunct Lecturer, Department of Community Health Sciences, University of Calgary. “Seroprevalence studies therefore estimate the number of people with some form of immunity to SARS-CoV-2, the virus that causes COVID-19, although it’s still unclear how long that immunity lasts.”
Compiling data from these global surveys provides insight on variations with which jurisdictions have tracked the pandemic with diagnostic testing. “We found important differences when comparing infection rates from diagnostic testing, which indicates acute infection, and antibody data, which indicate previous infection. In some areas of the world, there were six times more infections identified using antibody results than reported by diagnostic testing. This indicates there has been substantial infection spread not captured by reported case counts, likely due to a slow ramp-up of diagnostic testing in some cases, or inequitable access to it,” says Dr. Matthew Cheng, Assistant Professor, McGill University, Scientific Advisor for the CITF and co-senior author on the article.
The study also highlights major inequities in the pandemic impact and response. “Although antibody prevalence was low in the general population, there were significant differences in infection burden when stratified by demographics. Infection rates were higher in Black, Asian, and Indigenous people - indicating the need to prioritize protecting the hardest-hit populations through vaccine, workplace and community efforts,” says Rahul Arora. “Additionally, only 23% of the studies were conducted in low- and middle-income countries. The global community needs to come together to bolster pandemic preparedness and accessibility to research and public health tools.”
“This study serves as a vital baseline measurement of the world’s burden of infection, pre-vaccination, and highlights the imperative of equitable access to vaccines to bring the COVID-19 pandemic under control everywhere,” says Dr. Tim Evans, Executive Director of the COVID-19 Immunity Task Force and a co-author of the study.
As the pandemic persists, the group plans to continue harnessing antibody data to inform the public health response. Beyond the systematic review, SeroTracker’s database and dashboard continues to evolve. On the website, new results are being uploaded weekly. The WHO, Gates Foundation, McKinsey, Forbes and New York Times, among others, have used the dataset to inform their work.
“SeroTracker has created a method for rapid synthesis of real-world data that has informed science, investments, and policy-making in multiple aspects of the pandemic response, such as calculating infection fatality and identifying optimal vaccine trial sites,” says Arora. “Our long-term vision is to use data to enable rapid, effective, and equitable responses to pandemics. We are exploring the adaptability of our data platform to achieve this.”
SeroTracker is a dashboard and data platform for COVID-19 antibody testing studies, or serosurveys. The platform is a global collaboration of over 20 researchers, engineers, and physicians from six universities in Canada, the UK, and the United States. SeroTracker is funded by the Government of Canada through its COVID-19 Immunity Task Force, as well as by the World Health Organization, and the Canadian Medical Association. Visit the interactive dashboard at https://serotracker.com/en/Explore.
About the COVID-19 Immunity Task Force
The Government of Canada established the COVID-19 Immunity Task Force in late April 2020. The Task Force is overseen by a Leadership Group of volunteers that includes leading Canadian scientists and experts from universities and healthcare facilities across Canada who are focused on understanding the nature of immunity arising from the novel coronavirus that causes COVID-19. To that end, the CITF is supporting numerous studies to determine the extent of SARS-CoV-2 infection in Canada (in the general population as well as in specific communities and priority populations), understand the nature of immunity following infection, develop improved antibody testing methods, and help monitor the effectiveness and safety of vaccines as they are rolled out across Canada. The Task Force and its Secretariat accordingly work closely with a range of partners, including governments, public health agencies, institutions, health organizations, research teams, and other task forces, and engage communities and stakeholders. Most recently, the Task Force has been asked to support vaccine surveillance, effectiveness, and safety as part of its overall objective to generate data and ideas that inform interventions aimed at slowing—and ultimately stopping—the spread of SARS-CoV-2 in Canada. For more information visit: www.covid19immunitytaskforce.ca
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
